Incyte has initiated a Phase I clinical trial of INCB13739, an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears
to be critical to the development of Type 2 diabetes.
The trial is a
double-blind, placebo-controlled, single- and multiple-dose-rising study designed
to assess the safety and pharmacokinetics of INCB13739 in healthy volunteers.
The program will also evaluate the ability of INCB13739 to inhibit 11beta-HSD1
activity in adipose tissue and liver of high-body mass index individuals. Preclinical
studies have shown that 11beta-HSD1 activity in these two tissues may be a primary
driver of insulin resistance and diabetes.
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Complaint Handling, Process Controls Lacking at Battery Maker Alpha Source
Complaint records lacked adequate documentation of the root cause or corrective actions taken.
FDA Approves Treatment for Thrombocytopenia
Both dosage levels of Doptelet led to a higher proportion of patients with increased platelet counts.